JPH06345664A - New composition for suppressing elevation of blood pressure - Google Patents
New composition for suppressing elevation of blood pressureInfo
- Publication number
- JPH06345664A JPH06345664A JP5140868A JP14086893A JPH06345664A JP H06345664 A JPH06345664 A JP H06345664A JP 5140868 A JP5140868 A JP 5140868A JP 14086893 A JP14086893 A JP 14086893A JP H06345664 A JPH06345664 A JP H06345664A
- Authority
- JP
- Japan
- Prior art keywords
- cgp
- blood pressure
- whey
- suppressing
- elevation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、ホエー由来の血圧上昇
抑制用組成物と、その医薬、食品、飼料への応用に関す
る。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whey-derived composition for suppressing an increase in blood pressure and its application to medicines, foods and feeds.
【０００２】[0002]
【従来の技術・発明が解決しようとする課題】カゼイノ
グリコペプチド（以下「ＣＧＰ」と略す）は、チーズホ
エー、ホエー蛋白質、ホエーミネラル等に含まれる糖ペ
プチドであり、種々の生物活性を有することが知られて
いる。BACKGROUND OF THE INVENTION Caseinoglycopeptide (hereinafter abbreviated as "CGP") is a glycopeptide contained in cheese whey, whey protein, whey mineral, etc., and has various biological activities. It is known.
【０００３】ＣＧＰの生物活性としては、これまでに、
インフルエンザウイルスに対する抗活性、コレラトキシ
ンに対する中和活性、イヌの食欲を減少させる作用等が
知られている。このように、ＣＧＰは種々の生物活性を
有することから、これらの特性が産業上有効利用され得
る可能性を有している物質であるといえる。The biological activity of CGP has hitherto been:
It is known to have an anti-activity against influenza virus, a neutralizing activity against cholera toxin, an action of reducing dog's appetite, and the like. Thus, since CGP has various biological activities, it can be said that these properties are substances with the possibility of being effectively utilized in industry.
【０００４】しかし、ＣＧＰに血圧上昇抑制作用がある
ことは今まで全く知られていなかった。However, it has not been known at all until now that CGP has a blood pressure elevation suppressing effect.
【０００５】[0005]
【課題を解決するための手段】本発明者は、ＣＧＰの新
たな作用について研究を重ねた結果、ＣＧＰをヒト或い
は動物に経口投与すると血圧の上昇が抑制されるという
ことを見いだし、この知見に基づいて本発明を完成する
に至った。Means for Solving the Problems As a result of repeated studies on the new action of CGP, the present inventor has found that oral administration of CGP to humans or animals suppresses an increase in blood pressure. Based on this, the present invention has been completed.
【０００６】すなわち本発明は、カゼイノグリコペプチ
ドを有効成分として含有する血圧上昇抑制用組成物に関
する。That is, the present invention relates to a composition for suppressing an increase in blood pressure, which contains caseinoglycopeptide as an active ingredient.
【０００７】また、本発明は、カゼイノグリコペプチド
およびカリウムを含有する血圧上昇抑制用組成物に関す
る。The present invention also relates to a composition for suppressing an increase in blood pressure, which contains caseinoglycopeptide and potassium.
【０００８】更に、本発明は、上記の血圧上昇抑制用組
成物のうちいずれかを含有する食品および飼料に関す
る。Further, the present invention relates to foods and feeds containing any of the above-mentioned compositions for suppressing blood pressure increase.
【０００９】本発明で用いられるＣＧＰは、どのような
製法によって得られたものであってもよく、例えば、チ
ーズホエー、ホエータンパク質、ホエーミネラル等を出
発物質とし、この出発物質のｐＨを３〜６に調整し、加
熱・冷却してアルコール（エタノールが好ましい）を添
加後、一定時間静置した混合物を遠心分離し、上澄み液
をイオン交換クロマトグラフィーにかけて吸着・溶離し
て得られた液を濃縮すること（特開平４−２４３８９８
号公報参照）、により得られる。The CGP used in the present invention may be obtained by any production method, for example, cheese whey, whey protein, whey mineral, etc. as a starting material, and the pH of the starting material is 3 to 3. After adjusting to 6, heating and cooling, adding alcohol (preferably ethanol), centrifuging the mixture that was allowed to stand for a certain period of time, and subjecting the supernatant liquid to ion exchange chromatography to adsorb and elute, and concentrate the resulting liquid What to do (JP-A-4-243898)
(See Japanese Patent Laid-Open Publication).
【００１０】また、例えば、カゼイン溶液からレンネッ
トカゼインカードを調製する際に得られる排出液を原料
とし、この排出液のｐＨを酸性にすることによって生成
する沈澱を除去し、得られた上澄みを脱塩処理してＣＧ
Ｐを製造する方法（特開昭６３−２８４１９９号公報参
照）、ＣＧＰを含有する乳質原料物質をｐＨ４未満に調
整した後、分画分子量１０，０００〜５０，０００の膜
を用いて限外濾過処理を行って得られた濾過液を分画分
子量５０，０００以下の膜を用いて濃縮する方法（特開
平２−２７６５４２号公報参照）などを用いてもよい。Further, for example, the effluent obtained when preparing rennet casein curd from a casein solution is used as a raw material, and the precipitate produced by acidifying the pH of this effluent is removed, and the resulting supernatant is Desalination treatment and CG
A method for producing P (see JP-A-63-284199), a dairy raw material containing CGP is adjusted to pH less than 4, and then ultrafiltration is performed using a membrane having a molecular weight cutoff of 10,000 to 50,000. You may use the method (refer Unexamined-Japanese-Patent No. 2-276542) etc. which concentrates the filtrate obtained by performing a process using the membrane of molecular weight cut off 50,000 or less.
【００１１】このＣＧＰは、有用な食品素材であるホエ
ー由来のものであり、医薬として用いても極めて安全性
が高く、高血圧症の予防に用いることができる。また、
これを食品として日常生活において摂取することによ
り、高血圧症の予防効果が期待できる。さらにＣＧＰを
カリウムと併用することでより優れた効果をもたらす。[0011] This CGP is derived from whey, which is a useful food material, has extremely high safety even when used as a medicine, and can be used for prevention of hypertension. Also,
By ingesting this as a food in daily life, a preventive effect on hypertension can be expected. Further, by using CGP in combination with potassium, more excellent effects are brought about.
【００１２】ＣＧＰを血圧上昇抑制剤として使用する場
合、投与方法は経口投与によるのがよく、投与量は症
状、年令等により異なるが、ヒト成人ひとりあたり１日
量１〜１０ｇの範囲で使用することにより所期の効果が
得られる。When CGP is used as an antihypertensive agent, the administration method is preferably oral administration, and although the dose varies depending on the symptoms, age, etc., it is used in the range of 1 to 10 g per day for an adult human. By doing so, the desired effect can be obtained.
【００１３】この経口投与に適した製剤形態としては例
えば、錠剤、丸剤、散剤、液剤（ドリンク剤）、顆粒
剤、カプセル剤等が挙げられる。これらの製剤を調製す
るのには、通常使用される充填剤、増量剤、結合剤、付
湿剤、崩壊剤、表面活性剤、滑沢剤、希釈剤あるいは賦
形剤等を使用でき、一般の製剤化技術によって調製でき
る。Examples of the dosage form suitable for oral administration include tablets, pills, powders, liquids (drinks), granules, capsules and the like. To prepare these formulations, commonly used fillers, fillers, binders, moisturizers, disintegrants, surfactants, lubricants, diluents or excipients, etc. can be used. It can be prepared by the formulation technology of.
【００１４】また、ＣＧＰは種々の食品や飼料に添加し
て摂取させることもできる。ＣＧＰの添加に適した食品
としては、菓子類、アイスクリーム、ヨーグルト、スポ
ーツ飲料等が挙げられる。また、ＣＧＰは種々の家畜用
飼料および愛玩動物用飼料に添加することができる。CGP can also be ingested by adding it to various foods and feeds. Foods suitable for the addition of CGP include confectionery, ice cream, yogurt, sports drinks and the like. Further, CGP can be added to various livestock feeds and pet feeds.
【００１５】[0015]
【作用】ＣＧＰの血圧上昇抑制作用については、以下に
示す実験例「ＣＧＰによるラットの血圧上昇抑制作用」
により確認した。[Action] Regarding the blood pressure elevation inhibitory action of CGP, the experimental example shown below "CGP inhibits blood pressure elevation in rats"
Confirmed by.
【００１６】[0016]
ＣＧＰによるラットの血圧上昇抑制作用 〈目的〉血圧上昇前のＳＨＲ（高血圧自然発症ラット）
に、食塩を飼料中に負荷し、ＣＧＰを与えた場合と与え
なかった場合の血圧変化を比較した。Suppressive effect of blood pressure increase in rats by CGP <Purpose> SHR (spontaneously hypertensive rat) before blood pressure increase
In addition, changes in blood pressure were compared between cases where salt was loaded in the diet and CGP was given and where it was not given.
【００１７】〈実験方法〉５週令雄性ＳＨＲ（１５匹）
を２群（対照群７匹、ＣＧＰ群８匹）に分け下記の飼料
ならびに処置を行いＳＰＦ（無菌）条件下飼育した。飲
水量は３週次まで５０ｍｌ／匹とし、その後自由に摂水
させた。<Experimental method> 5-week-old male SHR (15 animals)
Were divided into 2 groups (7 animals in the control group and 8 animals in the CGP group), and the animals were bred under SPF (sterile) conditions by the following feed and treatment. The water intake was 50 ml / animal until the third week, and water was then freely given.
【００１８】対照群：５．７％ＮａＣｌ，１．９２％Ｋ
Ｃｌ含有粉末飼料 ＣＧＰ：５．７％ＮａＣｌ，１．９２％ＫＣｌ含有粉末
飼料およびＣＧＰ２０ｍｇ＊／ｄａｙ／ｒａｔ（ＣＧＰ
１ｍｇ／ｍｌ含有水２０ｍｌ／ｄａｙ） 〈測定項目〉体重および血圧を週１回測定した。Control group: 5.7% NaCl, 1.92% K
Cl-containing powdered feed CGP: 5.7% NaCl, 1.92% KCl-containing powdered feed and CGP 20 mg * / day / rat (CGP
Water containing 1 mg / ml, 20 ml / day) <Measurement Items> Body weight and blood pressure were measured once a week.
【００１９】結果を図１および図２に示す。The results are shown in FIGS. 1 and 2.
【００２０】〈結果〉体重増加は２群で有意な差異はみ
られなかった（図１）。血圧は実験開始５週までの結果
でも２群間に有意な差異（分散分析による有意差：Ｐ＜
０．０１）があり、５週次の血圧（平均±標準偏差）は
対照群：２３５±８、ＣＧＰ群：２１９±１０ｍｍＨｇ
であった（図２）。<Results> There was no significant difference in weight gain between the two groups (Fig. 1). Blood pressure was significantly different between the two groups even in the results up to the 5th week of the experiment (significant difference by analysis of variance: P <
0.01), and blood pressure (mean ± standard deviation) at the 5th week was 235 ± 8 for the control group and 219 ± 10 mmHg for the CGP group.
Was (Fig. 2).
【００２１】〈考察〉ＣＧＰ群の血圧上昇が有意に抑制
されたことからＣＧＰには血圧上昇抑制作用があるとい
える。また、各群の体重に大きい変化がみられなかった
がＣＧＰ群の体重は一定量の飲水を与えた最初の３週間
低下傾向にあった。その後自由摂水とすると対照群と変
化がなくなった。この結果からみて、一定量飲水した期
間のＣＧＰ群の体重低下はおそらく利尿が促進されたた
めと考えられる。自由摂水させた時点から２群の血圧は
大きな差異を示すことからもそのことが伺える。<Discussion> Since the blood pressure increase in the CGP group was significantly suppressed, it can be said that CGP has a blood pressure increase suppressing action. Although there was no significant change in the body weight of each group, the body weight of the CGP group tended to decrease for the first 3 weeks after giving a certain amount of water. After that, when water was freely fed, there was no difference from the control group. From this result, it is considered that the decrease in body weight of the CGP group during the period of drinking a certain amount of water was probably due to the promotion of diuresis. This can be seen from the fact that the blood pressures of the two groups show a large difference from the time of free watering.
【００２２】以下に参考例および実施例により本発明を
更に詳細に説明するが、本発明はこれらに限定されるも
のではない。The present invention will be described in more detail below with reference to Reference Examples and Examples, but the present invention is not limited thereto.
【００２３】[0023]
【参考例】 ＣＧＰの製造 １００ｇの甘性チーズホエー粉末（四ツ葉乳業株式会社
製）を蒸留水に加えて１０％（Ｗ／Ｖ）溶液１リットル
を作製した。この１０％溶液を１ＮＨＣｌでｐＨ６．０
に調整し、９８℃で１時間加熱した。加熱終了後、この
溶液を４℃に冷却し、５０％エタノールを１リットル加
えて、４℃で３時間静置した。次いで、この溶液を９０
００Ｇで３０分間遠心分離して沈澱物を除去した。残っ
た上澄み液を１ＮＮＨ4 ＯＨでｐＨ９．０に調整し、
０．０２−１．０Ｍの炭酸水素アンモニウム濃度勾配法
を用いてＤＥＡＥ−Ｔｏｙｏｐｅａｒｌ ６５０Ｍカラ
ムクロマトグラフにかけた。次いで、吸着したＣＧＰを
０．３Ｍの炭酸水素アンモニウムを用いて溶出した。Ｃ
ＧＰを含む溶出液を常法により減圧下で濃縮した後、凍
結乾燥しＣＧＰ粉末を得た。ＣＧＰの収量は１．１ｇで
あった。Reference Example Production of CGP 100 g of sweet cheese whey powder (manufactured by Yotsuba Dairy Co., Ltd.) was added to distilled water to prepare 1 liter of a 10% (W / V) solution. This 10% solution is pH 6.0 with 1N HCl.
And heated at 98 ° C. for 1 hour. After heating, this solution was cooled to 4 ° C, 1 liter of 50% ethanol was added, and the mixture was allowed to stand at 4 ° C for 3 hours. This solution is then added to 90
The precipitate was removed by centrifugation at 00G for 30 minutes. The remaining supernatant was adjusted to pH 9.0 with 1N NH 4 OH,
DEAE-Toyopearl 650M column chromatograph was run using a 0.02-1.0M ammonium bicarbonate gradient method. The adsorbed CGP was then eluted with 0.3M ammonium hydrogen carbonate. C
The eluate containing GP was concentrated under reduced pressure by a conventional method and then freeze-dried to obtain CGP powder. The yield of CGP was 1.1 g.
【００２４】[0024]
【実施例１】ＣＧＰ２００ｍｇ、アビセル７８０ｍｇ、
ステアリン酸マグネシウム１０ｍｇおよび硬化油１０ｍ
ｇを混合、直接打錠し、錠剤を得た。Example 1 CGP 200 mg, Avicel 780 mg,
Magnesium stearate 10 mg and hydrogenated oil 10 m
g was mixed and directly compressed into tablets to obtain tablets.
【００２５】[0025]
【実施例２】ＣＧＰ２００ｍｇ、コーンスターチ７００
ｍｇおよびヒドロキシプロピルセルロース１００ｍｇを
用いて、日局製剤総則の顆粒剤の製法に準じて顆粒剤を
得た。[Example 2] CGP 200 mg, corn starch 700
Using 100 mg of hydroxypropylcellulose and 100 mg of hydroxypropyl cellulose, granules were obtained according to the method for producing granules according to the general rules of the Japanese Pharmacopoeia.
【００２６】[0026]
【実施例３】ＣＧＰ１０ｇを１リットルのヨーグルトに
添加した。Example 3 10 g of CGP was added to 1 liter of yogurt.
【００２７】[0027]
【実施例４】ＣＧＰ２０ｇを５００ｇのみそに添加し
た。Example 4 20 g of CGP was added to 500 g of miso.
【００２８】[0028]
【発明の効果】以上述べた通り、ＣＧＰは血圧の上昇を
抑制する作用を持ち、しかもホエー由来のものなので安
全性も高い。したがって本発明の組成物は高血圧症の予
防効果を持つ医薬、食品に応用できる優れたものである
ということができる。As described above, CGP has an action of suppressing an increase in blood pressure, and is highly safe because it is derived from whey. Therefore, it can be said that the composition of the present invention is excellent in application to medicines and foods having a preventive effect on hypertension.
【図１】ＣＧＰを与えた場合と与えない場合のラットの
体重変化を表すグラフである。FIG. 1 is a graph showing changes in body weight of rats with and without CGP.
【図２】ＣＧＰを与えた場合と与えない場合のラットの
血圧変化を表すグラフである。FIG. 2 is a graph showing changes in blood pressure of rats with and without CGP.
フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ｃ０７Ｋ 15/24 8318−4Ｈ Continuation of the front page (51) Int.Cl. 5 Identification number Office reference number FI technical display area C07K 15/24 8318-4H
Claims (4)
て含有する血圧上昇抑制用組成物。1. A composition for suppressing an increase in blood pressure, which comprises caseinoglycopeptide as an active ingredient.
を含有する血圧上昇抑制用組成物。2. A composition for suppressing an increase in blood pressure, which comprises caseinoglycopeptide and potassium.
する食品。3. A food containing the composition according to claim 1.
する飼料。4. A feed containing the composition according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5140868A JPH06345664A (en) | 1993-06-11 | 1993-06-11 | New composition for suppressing elevation of blood pressure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5140868A JPH06345664A (en) | 1993-06-11 | 1993-06-11 | New composition for suppressing elevation of blood pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06345664A true JPH06345664A (en) | 1994-12-20 |
Family
ID=15278621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5140868A Pending JPH06345664A (en) | 1993-06-11 | 1993-06-11 | New composition for suppressing elevation of blood pressure |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06345664A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039878A1 (en) * | 1995-06-07 | 1996-12-19 | The Pillsbury Company | Method of making frozen compositions |
| GR1002668B (en) * | 1996-03-15 | 1997-04-14 | N | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt. |
| WO2001085984A1 (en) * | 2000-05-08 | 2001-11-15 | Davisco Foods International, Inc. | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| US6630320B1 (en) * | 2000-05-08 | 2003-10-07 | Devisco Foods International, Inc. | Treatment of hypertension in mammals with hydrolyzed whey proteins |
| EP1350515A1 (en) * | 2002-04-05 | 2003-10-08 | Btg International Limited | Low-dose potassium supplementation for the prevention and treatment of hypertension |
| WO2003086423A1 (en) * | 2002-04-05 | 2003-10-23 | Btg International Limited | Low-dose potassium supplementation for the prevention and treatment of hypertension |
| WO2004086880A1 (en) * | 2003-03-28 | 2004-10-14 | Kikkoman Corporation | Sodium chloride-containing foods and drinks |
| US6919314B1 (en) | 1998-06-17 | 2005-07-19 | New Zealand Dairy Board | Bioactive whey protein hydrolysate |
| US6998259B1 (en) | 1999-05-20 | 2006-02-14 | Davisco Foods International | Enzymatic treatment of whey proteins for the production of antihypertensive peptides and the resulting products |
| JP2008537476A (en) * | 2005-02-24 | 2008-09-18 | ディーエスエム アイピー アセッツ ビー．ブイ． | Antihypertensive peptide derived from glycomacropeptide |
-
1993
- 1993-06-11 JP JP5140868A patent/JPH06345664A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039878A1 (en) * | 1995-06-07 | 1996-12-19 | The Pillsbury Company | Method of making frozen compositions |
| GR1002668B (en) * | 1996-03-15 | 1997-04-14 | N | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt. |
| WO1997034496A3 (en) * | 1996-03-15 | 1997-11-20 | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt | |
| US6919314B1 (en) | 1998-06-17 | 2005-07-19 | New Zealand Dairy Board | Bioactive whey protein hydrolysate |
| US6998259B1 (en) | 1999-05-20 | 2006-02-14 | Davisco Foods International | Enzymatic treatment of whey proteins for the production of antihypertensive peptides and the resulting products |
| WO2001085984A1 (en) * | 2000-05-08 | 2001-11-15 | Davisco Foods International, Inc. | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| US6630320B1 (en) * | 2000-05-08 | 2003-10-07 | Devisco Foods International, Inc. | Treatment of hypertension in mammals with hydrolyzed whey proteins |
| EP1287159A4 (en) * | 2000-05-08 | 2005-02-09 | Davisco Foods Int Inc | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| EP1350515A1 (en) * | 2002-04-05 | 2003-10-08 | Btg International Limited | Low-dose potassium supplementation for the prevention and treatment of hypertension |
| WO2003086423A1 (en) * | 2002-04-05 | 2003-10-23 | Btg International Limited | Low-dose potassium supplementation for the prevention and treatment of hypertension |
| WO2004086880A1 (en) * | 2003-03-28 | 2004-10-14 | Kikkoman Corporation | Sodium chloride-containing foods and drinks |
| JP2008537476A (en) * | 2005-02-24 | 2008-09-18 | ディーエスエム アイピー アセッツ ビー．ブイ． | Antihypertensive peptide derived from glycomacropeptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2039365B1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
| KR101122843B1 (en) | Sustained improver of muscular fatigue | |
| JP6669750B2 (en) | Composition for inhibiting serum carnosine degrading enzyme containing cyclic dipeptide | |
| WO2019203136A1 (en) | Food composition for improving cognitive function, cognitive function improvement agent, and production method thereof | |
| JPH06345664A (en) | New composition for suppressing elevation of blood pressure | |
| KR20100108557A (en) | Liver function-protecting agent | |
| JPH01294631A (en) | Remedy and preventive for diabetic disease, food and drink and table luxury | |
| WO2017119481A1 (en) | Cyclic dipeptide-containing composition for preventing neurological diseases | |
| JPWO2017119476A1 (en) | Composition for preventing neurological diseases | |
| WO2000006192A1 (en) | Liver function ameliorating agents | |
| JP3373544B2 (en) | Foods and drinks and pharmaceuticals with excellent calcium utilization that have the effect of alleviating dysmenorrhea | |
| WO2018117103A1 (en) | Composition for ameliorating peripheral nerve disorders | |
| JPH06165655A (en) | Composition for reducing cholesterol | |
| WO2010110439A1 (en) | Composition for regulating autonomic nervous activity and method for regulating autonomic nerve | |
| JPH10146166A (en) | Physiologically active composition | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JP2010229118A (en) | Lipase inhibitor | |
| JP2016108265A (en) | Persistent antioxidant | |
| JPH08242773A (en) | Method for producing calcium-casein phosphopeptide preparation, bone mineral reduction-inhibiting food and bone mineral reduction inhibitor | |
| JPH1059865A (en) | Antimycotic composition for oral administration | |
| JP2002080356A (en) | Preventing and treating agent for hypertension | |
| JP2008214241A (en) | Immunomodulator | |
| JPH0565295A (en) | New physilogically active peptide and gastric acid secretion suppressing agent, antiulcer agent, food and drink containing the active peptide as active component | |
| JPH0531525B2 (en) | ||
| JP2007055979A (en) | Recovery promoter from diarrhea by rotavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040615 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040813 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040910 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041130 |